Mechanism of ETI Therapy on NLRP3 Inflammasome in Cystic Fibrosis
Publisher：Unknown
·Published at: 2025-12-13
A discussion regarding how elexacaftor/tezacaftor/ivacaftor (ETI) therapy modulates NLRP3 inflammasome activity and contributes to the reduction of pro-inflammatory cytokines in cystic fibrosis patients.
Loading...